Scarica l'app Stockscreener
0.856
3.88%
0.032
Pre-mercato:
.86
0.004
+0.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
Can Citius Pharmaceuticals Inc lead its sector in growth2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn
Risk Report: What is Citius Pharmaceuticals Incs 5 year growth outlook2026 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn
Retail Trends: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Citius Pharmaceuticals accelerates clinical momentum for LYMPHIR as oncology interest climbs - Traders Union
Support Test: What is Citius Pharmaceuticals Incs 5 year growth outlookWeekly Gains Report & Safe Capital Allocation Plans - baoquankhu1.vn
Citius Pharmaceuticals, Inc. Files Form 8-K Current Report with SEC on April 6, 2026 - Minichart
Trading Recap: Why is Cincinnati Financial Corporation stock going upBull Run & AI Forecasted Entry/Exit Points - baoquankhu1.vn
EPS Watch: What is Citius Pharmaceuticals Incs 5 year growth outlookTrade Analysis Report & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Citius Pharmaceuticals elects board members and ratifies auditor at annual meeting - Investing.com Australia
Citius Pharmaceuticals elects board members and ratifies auditor at annual meeting By Investing.com - Investing.com South Africa
Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results - TipRanks
Shareholders keep Citius (NASDAQ: CTXR) board and approve Wolf as auditor - Stock Titan
CTXR SEC FilingsCitius Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CTXR Technical Analysis & Stock Price Forecast - Intellectia AI
Breakouts Watch: What is Citius Pharmaceuticals Incs 5 year growth outlookTrade Risk Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
CTXR Stock Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
Citius Oncology highlights early LYMPHIR commercial traction, expansion - TipRanks
Citius Oncology advances LYMPHIR launch and global expansion - TipRanks
Bond Watch: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Performance Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development - Finviz
Citius Pharmaceuticals subsidiary reports strong early uptake and broad payer coverage for LYMPHIR launch - TradingView — Track All Markets
Citius Oncology (CTXR) details early LYMPHIR launch uptake and $400M CTCL market - Stock Titan
Early LYMPHIR launch traction at Citius Oncology (Nasdaq: CTOR) - Stock Titan
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Hi - GuruFocus
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - PR Newswire
Citius Pharmaceuticals Inc (47N0.MU) balance sheet - Yahoo Finance UK
RSI Check: Is Citius Pharmaceuticals Inc stock good for income investors2026 Sector Review & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Citius Pharmaceuticals Inc (47N0.MU) insider ownership and holdings - Yahoo Finance UK
Citius Pharmaceuticals Inc (47N0.MU) recent insider transactions - Yahoo Finance UK
Rate Hike: Is Citius Pharmaceuticals Inc a cyclical or defensive stock2026 News Drivers & Low Risk Entry Point Guides - baoquankhu1.vn
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals to present CTCL clinical experience at USCLC Annual Workshop - tradersunion.com
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - BioSpace
Citius Oncology to Participate in USCLC Annual Workshop 2026, Hi - GuruFocus
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts - Finviz
Doctors treating rare skin lymphoma will discuss Citius drug LYMPHIR - Stock Titan
Aug Mood: Can Citius Pharmaceuticals Inc withstand a market correctionEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn
Downgrade Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn
If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - Stock Titan
Macro Review: Should I buy Citius Pharmaceuticals Inc stock nowSell Signal & Growth Oriented Trading Recommendations - baoquankhu1.vn
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Ideas Watch: Is Euroholdings Ltd stock trending bullishEarnings Recap Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Energy Moves: Does Citius Pharmaceuticals Inc align with a passive investing strategyMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn
D Boral Capital maintains Citius Pharmaceuticals (CTXR) buy recommendation - MSN
Activity Recap: Is Citius Pharmaceuticals Inc a potential multi baggerIPO Watch & Stepwise Trade Execution Plans - baoquankhu1.vn
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
Activity Recap: Is Citius Pharmaceuticals Inc stock good for income investors2026 Historical Comparison & AI Forecast Swing Trade Picks - baoquankhu1.vn
CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView — Track All Markets
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - The Chronicle-Journal
CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating fr - GuruFocus
Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - ca.investing.com
Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - Finviz
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - BioSpace
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks
Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com
LYMPHIR combo shows activity in gynecologic cancers for Citius (CTXR) - Stock Titan
Market Review: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Bull Bear: Is Citius Pharmaceuticals Inc in a long term uptrendPortfolio Risk Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):